Acadia Extends Trofinetide Patent Protection to 2041
Event summary
- Acadia Pharmaceuticals received a Notice of Allowance from the USPTO for a patent covering weight-banded dosing of trofinetide, extending U.S. patent protections to March 2041.
- The patent (U.S. Patent Application No. 17/590,496) covers trofinetide for the treatment of Rett syndrome.
- Current method-of-use patent for trofinetide expires in July 2036.
- Trofinetide is marketed as DAYBUE and DAYBUE STIX for Rett syndrome in adults and pediatric patients 2 years and older.
The big picture
Acadia's extended patent protection for trofinetide strengthens its position in the rare disease market, particularly for Rett syndrome. This move aligns with broader industry trends where biopharmaceutical companies seek to maximize the lifecycle of their key drugs through strategic patent extensions. The extended protection could enhance Acadia's ability to invest in further research and development while maintaining a competitive edge in the treatment of neurodevelopmental disorders.
What we're watching
- Patent Strategy
- How Acadia will leverage the extended patent protection to maintain market exclusivity for trofinetide.
- Commercialization
- Whether the extended patent life will support sustained revenue growth from DAYBUE and DAYBUE STIX.
- Competitive Dynamics
- The pace at which potential competitors may develop alternative treatments for Rett syndrome.